Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $29,726.55 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now directly owns 108,951 shares in the company, valued at $343,195.65. The trade was a 7.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Puma Biotechnology Stock Performance

Shares of PBYI stock traded down $0.17 during trading on Friday, reaching $2.95. 844,494 shares of the company’s stock were exchanged, compared to its average volume of 763,397. Puma Biotechnology, Inc. has a twelve month low of $2.22 and a twelve month high of $7.73. The firm’s fifty day moving average price is $2.99 and its 200-day moving average price is $2.98. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $144.81 million, a PE ratio of 6.15 and a beta of 1.08.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the prior year, the firm earned $0.12 earnings per share. As a group, sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Monday, December 23rd. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Institutional Investors Weigh In On Puma Biotechnology

Several hedge funds have recently bought and sold shares of PBYI. Rice Hall James & Associates LLC grew its position in shares of Puma Biotechnology by 3.3% in the second quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 4,686 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its holdings in Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 8,000 shares in the last quarter. Royce & Associates LP increased its position in Puma Biotechnology by 71.8% during the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 8,427 shares during the period. Squarepoint Ops LLC increased its position in Puma Biotechnology by 17.7% during the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 10,757 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Puma Biotechnology during the third quarter worth $34,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.